Related Experiment Video
Updated: Jun 22, 2026
05:17
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Novel 3,3'-diindolylmethane derivatives: synthesis and cytotoxicity, structural characterization in solid state
Dorota Maciejewska1, Magdalena Rasztawicka, Irena Wolska
1Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Warsaw, 02 097 Warsaw, Poland. domac@farm.amwaw.edu.pl
European Journal of Medicinal Chemistry
|June 23, 2009
Summary
New 3,3'-dindolylmethane derivatives show significant cytotoxicity against human melanoma cells. Halogen and nitro-substituted compounds effectively inhibit cancer cell viability at low micromolar concentrations.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Cancer Biology
Background:
- 3,3 -dindolylmethane (DIM) derivatives are recognized for their diverse biological activities.
- Melanoma remains a significant global health concern, necessitating the development of novel therapeutic agents.
Purpose of the Study:
- To synthesize and characterize novel 3,3 -dindolylmethane derivatives.
- To evaluate the in vitro cytotoxicity of these derivatives against human melanoma cell lines.
Main Methods:
- Synthesis of 3,3 -dindolylmethane derivatives.
- Structural characterization using solid-state (13)C CP/MAS NMR and X-ray diffraction.
- Cytotoxicity assays against ME18 and ME18/R human melanoma cell lines.
Main Results:
- Successful synthesis and structural confirmation of several 3,3 -dindolylmethane derivatives.
- Demonstrated significant cytotoxicity against human melanoma cell lines.
- Derivatives with fluoro, bromo, iodo, and nitro substituents exhibited 50% inhibition of cell viability at concentrations of 9.7–17.3 µM.
Conclusions:
- The synthesized 3,3 -dindolylmethane derivatives possess potent cytotoxic activity against human melanoma.
- Substituent modifications, particularly with halogens and nitro groups, enhance anti-melanoma efficacy.
- These compounds represent promising candidates for further development as melanoma therapeutics.
